| 0.996 | 0 | 0.996 | Insulin like growth factor 1 antagonist | | |
| 0.996 | 0 | 0.996 | Insulin growth factor antagonist | | |
| 0.98 | 0.001 | 0.98 | ALK inhibitor | | |
| 0.97 | 0 | 0.97 | Insulin receptor antagonist | | |
| 0.959 | 0.002 | 0.959 | Focal adhesion kinase 1 inhibitor | | |
| 0.928 | 0.004 | 0.928 | Tyrosine kinase inhibitor | | |
| 0.909 | 0.004 | 0.909 | Growth factor antagonist | | |
| 0.718 | 0.001 | 0.718 | Focal adhesion kinase 2 inhibitor | | |
| 0.62 | 0.024 | 0.62 | Cyclophilin D inhibitor | | |
| 0.596 | 0.005 | 0.596 | Src kinase inhibitor | | |
| 0.581 | 0.004 | 0.581 | c-Src kinase inhibitor | | |
| 0.532 | 0.024 | 0.532 | Angiogenesis inhibitor | | |
| 0.482 | 0.002 | 0.482 | Leucine-rich repeat kinase 2 inhibitor | | |
| 0.473 | 0.004 | 0.473 | Granulocyte macrophage colony stimulating factor antagonist | | |
| 0.444 | 0.005 | 0.444 | Epidermal growth factor receptor kinase inhibitor | | |
| 0.422 | 0.005 | 0.422 | Protein-tyrosine kinase (PTK, not ETK, WZC) inhibitor | | |
| 0.422 | 0.005 | 0.422 | Abl kinase inhibitor | | |
| 0.397 | 0.005 | 0.397 | Cyclin-dependent kinase 7 inhibitor | | |
| 0.399 | 0.01 | 0.399 | Bone formation stimulant | | |
| 0.33 | 0.003 | 0.33 | ZAP-70 protein tyrosine kinase inhibitor | | |
| 0.348 | 0.037 | 0.348 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | | |
| 0.427 | 0.123 | 0.427 | Antiinflammatory | | |
| 0.293 | 0.008 | 0.293 | Epidermal growth factor antagonist | | |
| 0.281 | 0.015 | 0.281 | Polo-like kinase-3 inhibitor | | |
| 0.242 | 0.005 | 0.242 | Tyk2 inhibitor | | |
| 0.261 | 0.027 | 0.261 | Growth factor agonist | | |
| 0.238 | 0.009 | 0.238 | ErbB-4 antagonist | | |
| 0.208 | 0.006 | 0.208 | EphB4 antagonist | | |
| 0.206 | 0.016 | 0.206 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | | |
| 0.227 | 0.053 | 0.227 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | | |
| 0.194 | 0.026 | 0.194 | Ephrin antagonist | | |
| 0.235 | 0.068 | 0.235 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | | |
| 0.181 | 0.014 | 0.181 | Hepatocyte growth factor antagonist | | |
| 0.205 | 0.039 | 0.205 | Lck kinase inhibitor | | |
| 0.203 | 0.041 | 0.203 | Vascular endothelial growth factor 3 antagonist | | |
| 0.176 | 0.013 | 0.176 | Stem cell growth factor agonist | | |
| 0.226 | 0.07 | 0.226 | Antimitotic | | |
| 0.163 | 0.013 | 0.163 | Polo-like kinase-1 inhibitor | | |
| 0.18 | 0.031 | 0.18 | TRKB antagonist | | |
| 0.187 | 0.045 | 0.187 | Proto-oncogene tyrosine-protein kinase Yes inhibitor | | |
| 0.171 | 0.031 | 0.171 | Aurora-C kinase inhibitor | | |
| 0.155 | 0.017 | 0.155 | ErbB-3 antagonist | | |
| 0.167 | 0.034 | 0.167 | Aurora-A kinase inhibitor | | |
| 0.141 | 0.011 | 0.141 | MAP3K7 inhibitor | | |
| 0.173 | 0.045 | 0.173 | Tyrosine-protein kinase receptor FLT3 inhibitor | | |
| 0.145 | 0.021 | 0.145 | Janus tyrosine kinase 2 inhibitor | | |
| 0.126 | 0.005 | 0.126 | Cyclin D3 inhibitor | | |
| 0.167 | 0.048 | 0.167 | Cyclin-dependent kinase inhibitor | | |
| 0.167 | 0.054 | 0.167 | Activin receptor-like kinase 2 inhibitor | | |
| 0.194 | 0.086 | 0.194 | Platelet aggregation inhibitor | | |
| 0.11 | 0.005 | 0.11 | MAP kinase 7 inhibitor | | |
| 0.123 | 0.02 | 0.123 | Syk tyrosine kinase inhibitor | | |
| 0.196 | 0.093 | 0.196 | ErbB-1 antagonist | | |
| 0.129 | 0.039 | 0.129 | Platelet activating factor alpha antagonist | | |
| 0.114 | 0.024 | 0.114 | Macrophage colony-stimulating factor 1 receptor antagonist | | |
| 0.127 | 0.038 | 0.127 | CDK/cyclin complex inhibitor | | |
| 0.152 | 0.063 | 0.152 | Tyrosine-protein kinase receptor antagonist | | |
| 0.107 | 0.02 | 0.107 | Polo-like kinase-2 inhibitor | | |
| 0.145 | 0.068 | 0.145 | MAP3K9 inhibitor | | |
| 0.144 | 0.068 | 0.144 | Protein-tyrosine kinase Lyn inhibitor | | |
| 0.108 | 0.032 | 0.108 | ErbB-2 antagonist | | |
| 0.108 | 0.033 | 0.108 | AXL receptor tyrosine kinase inhibitor | | |
| 0.105 | 0.031 | 0.105 | Janus tyrosine kinase 3 inhibitor | | |
| 0.109 | 0.035 | 0.109 | Platelet growth factor antagonist | | |
| 0.158 | 0.088 | 0.158 | Death-associated protein kinase 2 inhibitor | | |
| 0.119 | 0.051 | 0.119 | Platelet activating factor beta antagonist | | |
| 0.12 | 0.054 | 0.12 | Vascular endothelial growth factor 1 antagonist | | |
| 0.17 | 0.111 | 0.17 | EphB2 antagonist | | |
| 0.094 | 0.036 | 0.094 | Fibroblast growth factor 3 antagonist | | |
| 0.12 | 0.067 | 0.12 | TRKA antagonist | | |
| 0.108 | 0.055 | 0.108 | Cyclin-dependent kinase 9 inhibitor | | |
| 0.092 | 0.04 | 0.092 | Proto-oncogene tyrosine-protein kinase c-hck inhibitor | | |
| 0.156 | 0.107 | 0.156 | Ca2+/calmodulin-dependent protein kinase inhibitor | | |
| 0.07 | 0.026 | 0.07 | Bruton tyrosine kinase inhibitor | | |
| 0.072 | 0.029 | 0.072 | Cyclin-dependent kinase 6 inhibitor | | |
| 0.109 | 0.066 | 0.109 | EphA2 antagonist | | |
| 0.09 | 0.051 | 0.09 | Bcr-Abl kinase inhibitor | | |
| 0.071 | 0.034 | 0.071 | CDK2/cyclin E inhibitor | | |
| 0.044 | 0.01 | 0.044 | CDK6/cyclin D3 inhibitor | | |
| 0.065 | 0.032 | 0.065 | CDK4/cyclin D inhibitor | | |
| 0.066 | 0.034 | 0.066 | CDK4/cyclin D1 inhibitor | | |
| 0.069 | 0.042 | 0.069 | Cyclin-dependent kinase 4 inhibitor | | |
| 0.06 | 0.039 | 0.06 | CDK9/cyclin T1 inhibitor | | |
| 0.123 | 0.103 | 0.123 | Dual specificity tyrosine-phosphorylation regulated kinase 1B inhibitor | | |
| 0.1 | 0.081 | 0.1 | Aurora-B kinase inhibitor | | |
| 0.143 | 0.134 | 0.143 | Death-associated protein kinase 3 inhibitor | | |
| 0.058 | 0.049 | 0.058 | Cyclin A2 inhibitor | | |
| 0.073 | 0.065 | 0.073 | TIE-2 antagonist | | |
| 0.073 | 0.066 | 0.073 | TIE antagonist | | |
| 0.122 | 0.115 | 0.122 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | | |
| 0.105 | 0.098 | 0.105 | Ca2+/calmodulin-dependent kinase II delta inhibitor | | |
| 0.052 | 0.048 | 0.052 | Fibroblast growth factor 4 antagonist | | |
| 0.089 | 0.085 | 0.089 | Cyclin-dependent kinase 2 inhibitor | | |
| 0.081 | 0.079 | 0.081 | CDK2/cyclin A inhibitor | | |
| 0.078 | 0.077 | 0.078 | Fibroblast growth factor 1 antagonist | | |